Repository logo
 

Do CSF biomarkers and FDG PET imaging show sufficient clinical utility for diagnosis of dementia subtypes?

Accepted version
Peer-reviewed

No Thumbnail Available

Type

Article

Change log

Authors

Smailagic, Nadja 
Brayne, CEG 

Abstract

NICE recently published updated recommendations for diagnosing dementia and how people with this clinical syndrome navigate the care system. In this update, major changes from the previous version include the use of emerging diagnostic methods in research. NICE recommendations regarding the use of CSF biomarkers and FDG PET imaging for diagnosing dementia subtypes in specialist clinical setting are based on results from diagnostic test accuracy (DTA) studies identified and included in a systematic review conducted according to Cochrane DTA Handbook guidelines (http://methods.cochrane.org/sdt/handbook-dta-reviews). We have concerns about the way in which the evidence has been translated into practice recommendations.

Description

Keywords

Journal Title

BMJ: British Medical Journal

Conference Name

Journal ISSN

0959-535X

Volume Title

361

Publisher

BMJ
Sponsorship
Paul G Allen Family Foundation (12076)
During the development of this work, JP was an employee of NICE, which is commissioned and funded by the Department of Health to develop clinical guidelines. No authors received specific funding to write this summary.